The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Ibrutinib-rituximab safe and effective in the frontline for elderly MCL
Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, discusses the Phase II trial (NCT01880567) investigating the combination of ibrutinib with rituximab for the frontline treatment of elderly patients with mantle cell lymphoma (MCL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
